Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
April 19 2018 - 8:00AM
Business Wire
Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced the appointment
of Brant Biehn as Senior Vice President, Commercial Operations. Mr.
Biehn brings over 27 years of commercial planning, market
development and sales experience in the pharmaceutical
industry.
“We are delighted to welcome Brant to Vaxart. He is a seasoned
leader with a wealth of sales and marketing experience within the
pharmaceutical and vaccine industry,” said Wouter Latour, chief
executive office of Vaxart. “That combination will be invaluable as
we advance our therapeutic and prophylactic product candidates
through the clinic toward commercialization. We look forward to his
contributions as we further establish Vaxart as a leader in the
development of antivirals and vaccines.”
Prior to joining Vaxart, Mr. Biehn served as a consultant, where
his role included business development, investor relations, and
general management for a variety of pharmaceutical and medical
device companies. Earlier, he served as chief commercial officer at
Dynavax Technologies Corporation, where he helped raised
significant capital and was responsible for the development and
execution of Dynavax’s commercial strategy, including global sales,
marketing and supply chain management, leading a team of 70
professionals preparing to launch Heplisav®.
Before Dynavax, Mr. Biehn held sales and marketing positions of
increasing seniority at Merck, culminating in the position of
Global Brand Leader with global responsibility for the
manufacturing, commercial, clinical and regulatory acitivites for
vaccines such as ZOSTAVAX®, PNEUMOVAX®, RECOMBIVAX HB® and
VAQTA®.
Mr. Biehn holds a Bachelor of Science in Computer Science from
the Memorial University of Newfoundland.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet vaccines are
easier to distribute and administer than injectable vaccines, and
have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV). Vaxart is also developing several
small-molecule antiviral drug candidates, including teslexivir
(BTA074), an antiviral treatment for condyloma caused by HPV types
6 and 11. For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential”,
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates, clinical results and trial data, Vaxart’s
ability to obtain and maintain regulatory approval of its product
candidates and Vaxart’s reliance on third party funding and grants.
Vaxart may not actually achieve the plans, carry out the intentions
or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart makes,
that Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; and the risks described in the
“Risk Factors” sections of the Registration Statement on Form S-4
(file no. 333-222009) and of Vaxart’s periodic reports filed with
the SEC. Vaxart does not assume any obligation to update any
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180419005430/en/
Stern Investor RelationsCarl Mauch,
212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024